Mode
Text Size
Log in / Sign up
N/A Completed N=93 Randomized Double-blind Prevention

Transversus Abdominis Plane Block Versus Erector Spinae Plane Block

Postoperative Pain · Laparotomy
Source: ClinicalTrials.gov NCT03989570 ↗
Enrolled (actual)
93
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcomePrimary: Time of First Post Operative Analgesic Request — 14.9; 6.5; 2.8 Hour

Summary

The TAP block, first described by Rafi in 2001, is comprised of deposition of a local anesthetic into the anatomical plane between the internal oblique and transverses abdominis muscles, where thess thoracoabdominal nerves (T6-L1) contribute to the main sensory supply of the skin, muscles, and parietal peritoneum of the anterior abdominal wall. These nerves branch and communicate extensively with each other in the TAP . Erector spinae plane (ESP) block is a recently described interfascial block in which the local anaesthectic is placed over or below the plane of the erector spinae muscle, near where the spinal nerves come out from the spine before they start to divide. Some publications have shown its effectiveness in treating thoracic and abdominal postoperative pain. Postoperative pain is the major obstacle for early postoperative ambulation and increases the risk of venous thromboembolism, respiratory complications and prolongs the hospital stay. Parietal pain is the chief component of postoperative pain after abdominal surgeries. Large doses of opioids are required to mitigate this pain, but they are poorly tolerated. Multimodal analgesia is effective in handling postoperative pain and in attenuating the side effects of large doses of a single analgesic .

Outcome Measures

OutcomeResultp-value
PRIMARY
Time of First Post Operative Analgesic Request
14.9; 6.5; 2.8
PRIMARY
Postoperative Total Fentanyl Requirement
40.3; 111; 175
SECONDARY
Incidence of Any Adverse Events
0; 0; 0

Eligibility Criteria

Inclusion Criteria

  • 1. Age18-70 . 2. Both gender . 3 .Emergency laparotomies . 4. ASA I-III .

Exclusion Criteria

  • Drug allergy .
  • Morbid obesity (BMI >40 kg/m2) .
  • Psychiatric disorder .
  • Opioid dependence .
  • patient refuse
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03989570). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search